MHRA Class 2 Medicines Recall: Mynzepli 40 mg/mL solution for injection in pre-filled syringe (Advanz Pharma Limited)
MHRA Class 2 Medicines Recall: Mynzepli 40 mg/mL solution for injection in pre-filled syringe (Advanz Pharma Limited).
Drug alert number: EL(26)A/44
Date issued: 29 October 2026
Advanz Pharma Limited are recalling specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure.
DMRC reference number: DMRC-41252013
Company name: Advanz Pharma Limited
Medicine Details
Mynzepli 40 mg/mL solution for injection in pre-filled syringe (PL: 56734/0022)
Active Ingredient: aflibercept
SNOMED code: 45567511000001107
GTIN: 05021691005605
Affected Lot Batch Numbers:
| Batch No. | Expiry Date | Pack Size | First Distributed |
| 2325742 | Jun-2027 | 1 | 02/01/2026 |
| 2325726 | May-2027 | 1 | 10/10/2025 |
Background
Advanz Pharma Limited are recalling the specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure because a small variation in the size of the finger grip could affect how the medicine is administered and potentially pose a risk to patient safety. The finger grip/flange provides a platform/surface for better grip of the syringe. It allows the user to securely hold the pre-filled syringe while applying pressure to the plunger rod during product administration.
Advice for Healthcare Professionals
Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
Advanz Pharma have confirmed that other unaffected batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe are currently available for distribution.
View the alert here.
Advice for Patients
This is a Pharmacy and Wholesaler level recall, therefore no further action is required by patients.
This product is only administered by a qualified healthcare professional experienced in administering intravitreal injections.
Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Additional information
For all enquiries and information on this product, please email medicalinformation@advanzpharma.com, or telephone +44 (0) 208 588 9131.
